In the biotech space it's actually difficult to find young companies that don't look like multi-bagger opportunities through the eyes of young investors. Sadly, few of us look at the industry through young eyes for very long. With less than 10% of pre-clinical programs reaching commercial stages, investing in a startup biotech with intentions to develop, and then market its own compounds is riskier than jumping off a building in a homemade Batman suit. You don't need to suffer too many disasters before age sets in, and you begin looking for companies with some sort of safety net.
Luckily, there is a hybrid option for wide eyed biotech investors yearning for the potential of a huge payoff, without the threat...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|